PM-NPs address multi-drug resistance by enhancing cellular uptake and evading the P-glycoprotein efflux pump. They are exceptionally effective in synergistic treatments, demonstrated by studies showing complete tumor elimination through Chemo-Photothermal Therapy for hepatocellular carcinoma (HCC).
Platelet Membrane Coated Nanoparticle for Targeted Drug Delivery
Platelet membrane coated nanoparticles (PM-NPs) represent the future of drug delivery, offering unprecedented precision and biological compatibility. Creative Biolabs provides specialized development and manufacturing services for PM-NP delivery systems. We help clients overcome the major challenges of immune clearance, poor disease-site accumulation, and dose-limiting systemic toxicity for their critical therapeutic payloads.
Click Here to View more about our Service
Introduction to Platelet Membrane Coated Nanoparticles
PM-NPs are advanced biomimetic drug carriers created through a "top-down" engineering strategy. They consist of a synthetic inner core, typically made of materials like PLGA or lipids, which holds the therapeutic agent. This core is then precisely wrapped in an outer shell derived from natural platelet plasma membranes. The generation process involves three core steps: first, isolating and fragmenting pure platelet membranes; second, fabricating the synthetic core with the drug payload; and finally, using mechanical extrusion or sonication to uniformly cloak the core with the platelet membrane layer. This structure effectively camouflages the synthetic materials while retaining the platelet's vital surface functionality.
Fig.1 The fabrication process of platelet membrane-coated mesoporous silicon nanoparticle (PMSN).1
Advantages of Platelet Membrane Coated Nanoparticles
PM-NPs offer a significant upgrade over synthetic nanocarriers due to the biological intelligence inherited from the platelet membrane. Their key properties and advantages include:
Prolonged Systemic Circulation (Immune Evasion)
The presence of the surface protein CD47 acts as a crucial "don't eat me" signal. Its binding to SIRPα on macrophages actively suppresses phagocytosis, preventing rapid clearance by the mononuclear phagocyte system (MPS) and significantly prolonging the nanocarrier's half-life in the bloodstream.
Active Pathological Homing
PM-NPs retain key surface receptors like P-selectin (CD62P) and Integrins (αIIbβ3) which naturally home to sites of inflammation, vascular injury, and tumor microenvironments. This intrinsic targeting capability promotes rapid, reliable accumulation at the disease site.
Superior Target-to-Non-Target Ratios
The combination of immune evasion and active homing creates a powerful dual-action strategy. This maximizes the local therapeutic concentration while minimizing systemic exposure and potential off-target toxicity compared to passive delivery systems.
Enhanced Intracellular Drug Retention
The biomimetic shell facilitates superior cellular uptake while simultaneously helping the payload evade common mechanisms of drug resistance, such as the P-glycoprotein (P-gp) efflux pump pathway often seen in cancer cells, leading to better therapeutic efficacy.
Applications of Platelet Membrane Coated Nanoparticles
Oncology
Cardiovascular Disease
Leveraging the platelet's natural affinity for damaged vessels, PM-NPs actively target atherosclerotic plaques. They are used to deliver anti-inflammatory agents or specialized payloads like anti-CD47 antibodies to promote plaque stabilization and regression.
Neurotherapeutics
The bio-camouflaging and prolonged circulation are crucial for overcoming the challenging Blood-Brain Barrier (BBB) and Blood-Brain Tumor Barrier (BBTB), making them promising candidates for delivering agents to treat Glioblastoma (GBM).
Inflammatory Conditions
PM-NPs are naturally home to sites of inflammation, making them ideal carriers for targeted drug delivery in conditions like Rheumatoid Arthritis (RA), reducing systemic side effects.
Table.1 Examples of PM-NPs applications.
| Application Area | NP Core | Key Mechanism |
|---|---|---|
| Oncology (HCC) | PLGA / PPy Nanoparticles | Active Homing (P-selectin) & Synergistic PTT/Chemo |
| Atherosclerosis | Liposome, Lipid, Mesoporous Silica | Adhesion to Damaged Endothelium & Anti-CD47 Delivery |
| Glioblastoma (GBM) | PLGA / Polymeric Core | Immune Evasion (CD47) & Prolonged Circulation |
| Chronic Inflammation | Polymeric / Liposomal Core | P-selectin mediated targeting to synovium |
Creative Biolabs offers end-to-end development services for PM-NP delivery systems, accommodating various nanoparticle core types (PLGA, liposomes, gold nanorods). Leveraging our platform advantages in QA/QC and functional protein validation, we accelerate your biomimetic nano-drug delivery system (BNDDS) pipeline. Contact our R&D team today to consult on engineering a persistent and precision-targeted nanocarrier solution for your unique payload.
Reference
- Chen, Liang, et al. "Platelet membrane-coated nanocarriers targeting plaques to deliver anti-CD47 antibody for atherosclerotic therapy." Research (2022). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.34133/2022/9845459
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
